In recent years, the demand and complexity of vaccines continue to increase. In order to promote the development of glyco-based vaccines, CD BioGlyco has developed a series of outstanding vaccine development platforms by integrating various advanced technologies. We have the confidence to be your essential research assistant in the field of glycobiology.
Vaccines are one of the most cost-effective interventions to prevent infectious diseases, especially in developing countries where many diseases still need to be controlled. In the past period, people have controlled and eliminated many viral and bacterial infectious diseases (such as smallpox, polio, tetanus, etc.) through vaccines, greatly improving the quality of human life.
Glycoconjugate vaccine is obtained by covalently binding carbohydrates and protein carriers. Since the first glycoconjugate vaccine against Hib came out and became popular in 1987, scientists have begun to develop glyco- or glycoconjugate vaccines against viruses, protozoa, fungi, and cancer. Today, there are several licensed glycoconjugate vaccines, such as vaccines against Haemophilus influenzae, meningococcus serogroups, 10-13 serotypes of pneumococcus, and Salmonella typhi.
The development of vaccine is a complex process. CD BioGlyco has developed a glyco-based vaccine development platform to provide customers with better solutions for vaccine design, production, and optimization. We provide glycoprotein-based vaccine development, glycopeptide-based cancer vaccine development, carbohydrate-based vaccine development, and carbohydrate-based vaccine adjuvant development services to help customers accelerate their vaccine development and preclinical research to combat new infections and meet medical needs.
CD BioGlyco has developed specialized platforms and systematic solutions for the design, expression, and synthesis of glycoprotein vaccine candidates.
CD BioGlyco provides customers with carbohydrate synthesis, conjugation and carrier protein design services for vaccine development.
CD BioGlyco is a biotechnology company highly experienced in developing glycobiology-related products and services. To promote the development of glycol-based medicine, we have developed a series of glyco-based vaccine technology platforms to provide customers with comprehensive, high-quality, and affordable services.
If you are interested in our services, please contact us for more detailed information.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.